Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab
Hurwitz, M. E., et al. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL